Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

New Analogs of Mibefradil Created as Radiosensitizers for Glioblastoma

Oncotarget

May 5, 2021
Researchers from Yale University conducted a study to create mibefradil analogs as superior radiosensitizers in glioblastoma treatments. continue reading »

Behind the Study: Prognostic Role of mir-24-3p in Breast Cancer

Oncotarget

May 5, 2021
Researchers from NYU discuss their 2018 study published in Oncotarget, entitled, "Prognostic role of elevated mir-24-3p in breast cancer and its association with the metastatic process." continue reading »

Table of Contents: Oncotarget’s Volume 12, Issue #9

Oncotarget

May 5, 2021
Read short summaries of the latest research published by Oncotarget. continue reading »

Behind the Study: Symmetry and Symmetry Breaking in Cancer

Oncotarget

May 3, 2021
Researchers from Johns Hopkins School of Medicine describe their their 2017 study published by Oncotarget, entitled, "Symmetry and symmetry breaking in cancer: a foundational approach to the cancer problem." continue reading »

Oncotarget Sponsors Sergei Kurenov in the 2018 Ride for Roswell

Oncotarget

September 24, 2018
Oncotarget chose to sponsor Mr. Kurenov because his research—and all the vital research at Roswell Park—is central to what the journal stands for. Mr. Kurenov also shares a commitment to the free exchange of ideas and collaboration that Oncotarget promotes as an open-access journal. continue reading »